Central Nervous System Pharmacology Practice Questions

Q: Erenumab was approved by FDA in 2018 for which condition?

Migraine. **Explanation:** **Erenumab** is a breakthrough therapeutic agent in the management of **Migraine**. It is a fully human monoclonal antibody that specifically targets and blocks the **Calcitonin Gene-Related Peptide (CGRP) receptor**. CGRP is a potent neuropeptide and vasodilator that plays a central role in the pathophysiology of migraine by mediating pain transmission and neurogenic inflammation in the trigeminal system. By antagonizing this receptor, Erenumab effectively prevents the initiation of migraine attacks. It was the first FDA-approved drug (2018) in this class specifically for the **prophylaxis** of migraine in adults. **Analysis of Incorrect Options:** * **A & D (Phenylketonuria & Glycogen storage disorders):** These are metabolic/genetic disorders. Phenylketonuria is typically managed with dietary restriction or drugs like Sapropterin. Glycogen storage diseases are managed through nutritional support or enzyme replacement therapy (e.g., Alglucosidase alfa for Pompe disease), not monoclonal antibodies targeting neuropeptides. * **C (Hypertension):** While CGRP is a vasodilator, Erenumab is not used for hypertension. In fact, because it blocks a vasodilator, a potential side effect of Erenumab is a slight increase in blood pressure. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** CGRP Receptor Antagonist (Contrast this with *Fremanezumab* and *Galcanezumab*, which bind to the CGRP **ligand** itself). * **Route:** Administered via subcutaneous injection once monthly. * **Indications:** Prophylaxis of both episodic and chronic migraine. * **Side Effects:** Most common are injection site reactions and constipation. * **Other "Gepants":** Oral CGRP antagonists (e.g., Rimegepant, Ubrogepant) are used for acute treatment or prevention.

Q: All except one are centrally acting muscle relaxants. Which one is not?

Dantrolene sodium. **Explanation:** Skeletal muscle relaxants are broadly classified into two categories based on their site of action: **Centrally acting** (acting on the CNS) and **Peripherally acting** (acting at the neuromuscular junction or directly on the muscle fiber). **1. Why Dantrolene Sodium is the correct answer:** Dantrolene is a **peripherally acting** muscle relaxant. Unlike the other options, it does not work by depressing the central nervous system. Instead, it acts directly on the skeletal muscle by binding to the **Ryanodine Receptor (RyR1)** on the sarcoplasmic reticulum. This inhibits the release of calcium ions into the cytosol, thereby preventing muscle contraction (excitation-contraction uncoupling). **2. Analysis of Incorrect Options:** * **Meprobamate:** A carbamate derivative primarily used as an anxiolytic; it acts as a central depressant with muscle relaxant properties. * **Baclofen:** A **GABA-B agonist** that acts at the spinal cord level to reduce spasticity by inhibiting monosynaptic and polysynaptic reflexes. * **Diazepam:** A Benzodiazepine that acts via **GABA-A receptors** in the CNS to increase chloride conductance, leading to hyperpolarization and muscle relaxation. **Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Dantrolene is the DOC for **Malignant Hyperthermia** (caused by halothane/succinylcholine) and **Neuroleptic Malignant Syndrome (NMS)**. * **Baclofen** is the DOC for spasticity in Multiple Sclerosis but is ineffective in stroke. * **Tizanidine** is another high-yield centrally acting relaxant that works as a central **$\alpha_2$ agonist**. * **Side Effect:** A major side effect of Dantrolene is hepatotoxicity (monitor LFTs).

Q: Which of the following drugs has the highest potential to cause metabolic syndrome?

Clozapine. **Explanation:** Metabolic syndrome—characterized by significant weight gain, hyperlipidemia, and hyperglycemia (Type 2 Diabetes)—is a major adverse effect of **Second-Generation Antipsychotics (SGAs)**. **1. Why Clozapine is correct:** Clozapine (along with Olanzapine) carries the **highest risk** of metabolic syndrome. The underlying mechanism involves potent antagonism of **H1 (histamine)** and **5-HT2C (serotonin)** receptors, which leads to increased appetite, sedation, and direct interference with insulin sensitivity. Clozapine is associated with the most profound weight gain and the highest incidence of new-onset diabetes among all antipsychotics. **2. Analysis of incorrect options:** * **Quetiapine:** Also carries a high risk of metabolic syndrome, but it is clinically ranked lower than Clozapine and Olanzapine. * **Risperidone:** Carries a moderate risk. It is more notorious for causing hyperprolactinemia (due to D2 blockade in the tuberoinfundibular pathway) than severe metabolic derangement. * **Aripiprazole:** This is a partial D2 agonist and has the **lowest risk** (metabolically neutral) along with Ziprasidone and Lurasidone. **3. NEET-PG High-Yield Pearls:** * **Hierarchy of Metabolic Risk:** Clozapine = Olanzapine > Quetiapine > Risperidone > Aripiprazole = Ziprasidone. * **Monitoring:** Patients on Clozapine require mandatory monitoring of BMI, fasting blood glucose, and lipid profiles. * **Clozapine "Must-Knows":** It is the drug of choice for **resistant schizophrenia**, but its use is limited by **agranulocytosis** (requires regular CBC monitoring) and a lowered seizure threshold.

Q: Which of the following medications are used for migraine prophylaxis?

All of the above. Migraine prophylaxis is indicated when patients experience frequent attacks (usually >2-3 per month), severe disability, or failure of acute treatments. The goal is to reduce the frequency, severity, and duration of attacks. Why "All of the above" is correct: The medications listed represent three different pharmacological classes, all of which are first-line or second-line agents for migraine prevention: * **Verapamil (Option A):** While Beta-blockers (like Propranolol) are the most common cardiovascular drugs used, Verapamil (a Calcium Channel Blocker) is an effective alternative, particularly in patients with contraindications to beta-blockers or those with cluster headaches. * **Valproate (Option B):** Anticonvulsants like Sodium Valproate and Topiramate are highly effective. Valproate works by enhancing GABAergic inhibition and modulating glutamate, thereby reducing neuronal hyperexcitability [1]. * **Amitriptyline (Option C):** This Tricyclic Antidepressant (TCA) is a mainstay for prophylaxis. It works by inhibiting the reuptake of Serotonin and Norepinephrine and is particularly useful in patients with co-existing tension-type headaches or insomnia [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Propranolol is generally considered the first-line agent for migraine prophylaxis. * **Topiramate:** Often preferred in obese patients as it causes weight loss, whereas Valproate and Amitriptyline cause weight gain. * **Teratogenicity:** Avoid Valproate in women of childbearing age due to the risk of neural tube defects. * **Newer Agents:** CGRP antagonists (e.g., Erenumab) and Botox injections are used for chronic, refractory migraines. * **Acute Attack DOC:** Triptans (5-HT 1B/1D agonists) are the DOC for abortive therapy, not prophylaxis.

Q: Which of the following acts as an antagonist to the NMDA receptor?

Ketamine. **Explanation:** The **NMDA (N-methyl-D-aspartate) receptor** is an ionotropic glutamate receptor that plays a critical role in synaptic plasticity and memory. It is unique because it requires both glutamate binding and glycine as a co-agonist, along with the removal of a magnesium (Mg²⁺) plug via depolarization. **Ketamine** (Option A) is a dissociative anesthetic that acts as a **non-competitive antagonist** at the NMDA receptor. It binds to the phencyclidine (PCP) site inside the ion channel, effectively blocking the flow of cations. This blockade results in "dissociative anesthesia," characterized by profound analgesia, amnesia, and a cataleptic state. **Analysis of Incorrect Options:** * **Spermine (Option B):** This is a polyamine that acts as a **positive allosteric modulator** (agonist-like effect) at the NMDA receptor, facilitating its function rather than inhibiting it. * **Muscimol (Option C):** This is a potent, selective **GABA-A receptor agonist** derived from the mushroom *Amanita muscaria*. * **Baclofen (Option D):** This is a selective **GABA-B receptor agonist** used clinically as a centrally acting muscle relaxant to treat spasticity. **High-Yield Clinical Pearls for NEET-PG:** * **Other NMDA Antagonists:** Memantine (used in Alzheimer’s), Amantadine (Parkinson’s), Dextromethorphan (antitussive), and Phencyclidine (PCP). * **Ketamine Side Effects:** It is notorious for causing **emergence delirium** and hallucinations. It is also the anesthetic of choice in patients with **asthma** (due to bronchodilation) and **hypovolemic shock** (due to sympathetic stimulation). * **Contraindication:** Ketamine should be avoided in patients with increased intracranial pressure (ICP).

Q: Which of the following belongs to antifibrinolytic drugs?

Aprotinin. **Explanation:** The core concept here is the distinction between **fibrinolytics** (which break down clots) and **antifibrinolytics** (which prevent the breakdown of clots). **Why Aprotinin is Correct:** **Aprotinin** is a potent protease inhibitor that inhibits **plasmin**, the enzyme responsible for fibrinolysis (clot dissolution). By blocking plasmin and its precursor kallikrein, it stabilizes existing fibrin clots and reduces bleeding. It is clinically used to reduce blood loss during major surgeries, such as coronary artery bypass grafting (CABG). Other common antifibrinolytics include **Tranexamic acid** and **Epsilon-aminocaproic acid (EACA)**, which work by blocking the lysine-binding sites on plasminogen. **Why the Other Options are Incorrect:** * **Alteplase (A):** This is a recombinant Tissue Plasminogen Activator (rt-PA). It converts plasminogen to plasmin, thereby promoting the lysis of clots. It is used in acute ischemic stroke and MI. * **Urokinase (B):** An enzyme naturally produced by the kidneys that directly converts plasminogen to plasmin. It is a fibrinolytic agent. * **Reteplase (D):** A second-generation recombinant plasminogen activator (a derivative of t-PA) with a longer half-life than Alteplase. Like the others, it is a fibrinolytic used to dissolve thrombi. **High-Yield NEET-PG Pearls:** * **Mechanism Check:** Fibrinolytics = Plasminogen Activators; Antifibrinolytics = Plasmin Inhibitors/Plasminogen Activation Blockers. * **Tranexamic Acid:** 10 times more potent than EACA; widely used in trauma and postpartum hemorrhage (PPH). * **Aprotinin Caution:** Though effective, its use is limited due to risks of anaphylaxis and renal dysfunction. * **Antidote:** If a patient bleeds excessively due to Fibrinolytics (like Alteplase), the specific antidote is an Antifibrinolytic (like Tranexamic acid).

Q: Which of the following is an inverse agonist of the GABA receptor?

β-Carboline. ### Explanation The GABA-A receptor is a ligand-gated chloride channel with specific binding sites for various pharmacological agents. The effect of a drug depends on its **intrinsic activity** at the benzodiazepine (BZD) receptor site. **1. Why β-Carboline is Correct:** **β-Carbolines** (e.g., DMCM) act as **inverse agonists**. Unlike agonists that increase chloride channel opening frequency, inverse agonists bind to the BZD receptor and produce the **opposite physiological effect** of benzodiazepines. By decreasing the frequency of chloride channel opening, they reduce GABAergic inhibition, leading to **pro-convulsant, anxiogenic (anxiety-inducing), and stimulant effects.** **2. Analysis of Incorrect Options:** * **Benzodiazepines (Option A):** These are **full agonists** at the BZD site. They facilitate GABA action (positive allosteric modulators), increasing the frequency of chloride channel opening, which results in sedative, anxiolytic, and anticonvulsant effects. * **Flumazenil (Option B):** This is a **competitive antagonist**. It has high affinity but **zero intrinsic activity**. It occupies the BZD receptor to block the actions of both agonists (Benzodiazepines) and inverse agonists (β-Carbolines) but exerts no effect of its own. **3. NEET-PG High-Yield Clinical Pearls:** * **GABA-A vs. GABA-B:** GABA-A is ionotropic (Chloride channel); GABA-B is metabotropic (G-protein coupled, increases K+ conductance). * **Barbiturates vs. BZDs:** BZDs increase the **frequency** of channel opening; Barbiturates increase the **duration** of channel opening. * **Flumazenil Use:** It is the drug of choice for BZD overdose but can precipitate **seizures** in patients with long-term BZD dependence or tricyclic antidepressant co-ingestion. * **Z-drugs:** Zolpidem and Zopiclone act on the **α1 subunit** of the GABA-A receptor, specifically mediating sedation rather than muscle relaxation.

Q: According to signal transduction mechanisms, what type of receptor is the GABA-B receptor?

G protein-coupled receptor. ### Explanation The **GABA-B receptor** is a metabotropic receptor, meaning it exerts its effects through an intermediary signaling molecule. Specifically, it is a **G protein-coupled receptor (GPCR)** coupled to the **Gᵢ/Gₒ protein** subtype. **Mechanism of Action:** Activation of GABA-B receptors leads to: 1. **Inhibition of Adenylyl Cyclase:** Decreasing intracellular cAMP levels. 2. **Opening of K⁺ channels:** Causing potassium efflux and membrane hyperpolarization (postsynaptic effect). 3. **Closing of Ca²⁺ channels:** Inhibiting neurotransmitter release (presynaptic effect). --- ### Analysis of Incorrect Options: * **A. Ligand-gated ion channel receptor:** This describes the **GABA-A receptor**, which is an ionotropic receptor. Upon activation, it directly opens a chloride (Cl⁻) channel, leading to rapid hyperpolarization. * **B. Nuclear receptor:** These are intracellular receptors for lipid-soluble ligands (e.g., steroids, thyroid hormones) that act as transcription factors. GABA is a neurotransmitter that acts on cell-surface receptors. * **C. Enzyme-linked receptor:** These receptors (e.g., Insulin, Growth Factors) have intrinsic enzymatic activity (like Tyrosine Kinase). GABA-B signaling does not involve direct enzymatic activation. --- ### High-Yield Clinical Pearls for NEET-PG: * **Baclofen:** A selective **GABA-B agonist** used clinically as a centrally acting muscle relaxant to treat spasticity (e.g., in Multiple Sclerosis or spinal cord injuries). * **Location:** GABA-A is primarily postsynaptic, whereas GABA-B is found both **presynaptically** (acting as an autoreceptor) and postsynaptically. * **Response Time:** GABA-A mediates "fast" inhibitory postsynaptic potentials (IPSPs), while GABA-B mediates "slow" and prolonged IPSPs due to the second-messenger cascade.

Q: A 30-year-old theatre actress developed facial wrinkles. The treating physician advised local injections of a drug indicated in cervical dystonia, spastic disorders like cerebral palsy, and prophylaxis of migraine. The physician warned of potential side effects including dry mouth and blurred vision. The actress identified the drug's site of action as depicted in the accompanying figure. Which of the following drugs is being described?

Botulinum toxin. ***Botulinum toxin*** - Cleaves **SNARE proteins** (SNAP-25, syntaxin, synaptobrevin) at the **presynaptic terminal**, blocking **acetylcholine exocytosis** from nerve endings. - Used for **cosmetic wrinkles**, **cervical dystonia**, **cerebral palsy spasticity**, and **migraine prophylaxis**; causes **anticholinergic effects** like dry mouth and blurred vision. *Hemicholinium* - Blocks **choline reuptake** at the presynaptic terminal, depleting acetylcholine synthesis over time. - Not used clinically for cosmetic purposes or the mentioned conditions; primarily a research tool. *Vesamicol* - Inhibits **vesicular acetylcholine transporter (VAChT)**, preventing acetylcholine packaging into synaptic vesicles. - Research compound with no clinical applications for wrinkles, dystonia, or migraine prophylaxis. *Physostigmine* - **Acetylcholinesterase inhibitor** that acts in the **synaptic cleft**, increasing acetylcholine availability. - Used as antidote for **anticholinergic poisoning**; would worsen rather than treat spastic disorders and dystonia.

Q: A 30-year-old male presents with a history of abnormal, excessive blinking and grunting sounds. He has no control over these symptoms, which have increased in frequency. Which of the following medications can be used for the treatment of this condition?

Risperidone. ### Explanation **Diagnosis:** The clinical presentation of involuntary motor tics (excessive blinking) and vocal tics (grunting sounds) in a young patient is characteristic of **Tourette Syndrome (TS)**. **1. Why Risperidone is Correct:** The pathophysiology of Tourette Syndrome involves **dopaminergic overactivity** in the nigrostriatal pathway and basal ganglia. Treatment focuses on dopamine modulation. **Risperidone**, an atypical antipsychotic (D2 and 5-HT2A receptor antagonist), is a first-line pharmacological treatment for tics. It is often preferred over typical antipsychotics (like Haloperidol or Pimozide) due to a lower risk of extrapyramidal side effects (EPS) while effectively suppressing both motor and vocal tics. **2. Why the Other Options are Incorrect:** * **A. Carbamazepine:** An antiepileptic and sodium channel blocker used for focal seizures and trigeminal neuralgia; it has no role in treating tics. * **B. Imipramine:** A Tricyclic Antidepressant (TCA) used for nocturnal enuresis and depression. While some TCAs are used in ADHD, they are not indicated for tic disorders. * **C. Methylphenidate:** A CNS stimulant used for ADHD. It can actually **exacerbate or unmask tics** in susceptible individuals due to increased dopamine release. **3. NEET-PG High-Yield Pearls:** * **FDA-approved drugs for TS:** Haloperidol, Pimozide, and Aripiprazole. * **First-line non-pharmacological therapy:** Comprehensive Behavioral Intervention for Tics (CBIT). * **Alpha-2 Agonists:** Clonidine and Guanfacine are often used first-line if the patient has comorbid ADHD. * **Comorbidities:** ADHD and OCD are the most common psychiatric conditions associated with Tourette Syndrome.

Question 1

Erenumab was approved by FDA in 2018 for which condition?

Accepted Answer

Migraine

Answer

Phenylketonuria

Answer

Hypertension

Answer

Glycogen storage disorders

Question 2

All except one are centrally acting muscle relaxants. Which one is not?

Accepted Answer

Dantrolene sodium

Answer

Meprobamate

Answer

Baclofen

Answer

Diazepam

Question 3

Which of the following drugs has the highest potential to cause metabolic syndrome?

Accepted Answer

Clozapine

Answer

Risperidone

Answer

Quetiapine

Answer

Aripiprazole

Question 4

Which of the following medications are used for migraine prophylaxis?

Accepted Answer

All of the above

Answer

Verapamil

Answer

Valproate

Answer

Amitriptyline

Question 5

Which of the following acts as an antagonist to the NMDA receptor?

Accepted Answer

Ketamine

Answer

Spermine

Answer

Muscimol

Answer

Baclofen

Question 6

Which of the following belongs to antifibrinolytic drugs?

Accepted Answer

Aprotinin

Answer

Alteplase

Answer

Urokinase

Answer

Reteplase

Question 7

Which of the following is an inverse agonist of the GABA receptor?

Accepted Answer

β-Carboline

Answer

Benzodiazepines

Answer

Flumazenil

Answer

None of the above

Question 8

According to signal transduction mechanisms, what type of receptor is the GABA-B receptor?

Accepted Answer

G protein-coupled receptor

Answer

Ligand-gated ion channel receptor

Answer

Nuclear receptor

Answer

Enzyme-linked receptor

Question 9

A 30-year-old theatre actress developed facial wrinkles. The treating physician advised local injections of a drug indicated in cervical dystonia, spastic disorders like cerebral palsy, and prophylaxis of migraine. The physician warned of potential side effects including dry mouth and blurred vision. The actress identified the drug's site of action as depicted in the accompanying figure. Which of the following drugs is being described?

Accepted Answer

Botulinum toxin

Answer

Hemicholinium

Answer

Vesamicol

Answer

Physostigmine

Question 10

A 30-year-old male presents with a history of abnormal, excessive blinking and grunting sounds. He has no control over these symptoms, which have increased in frequency. Which of the following medications can be used for the treatment of this condition?

Accepted Answer

Risperidone

Answer

Carbamazepine

Answer

Imipramine

Answer

Methylphenidate

Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?